Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
(Thomson Reuters ONE) -
Novartis International AG /
Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained
Phase III efficacy and safety data
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Cosentyx(®) (secukinumab) is the first and only fully human IL-17A
inhibitor to show sustained skin clearance rates at 5 years in phase III in
psoriasis[1]
* Landmark data show that PASI 90 and PASI 100 response rates were nearly
100% maintained with Cosentyx from Year 1 to Year 5 in patients with
moderate-to-severe plaque psoriasis[1]
* 5-year data from a Phase III study reinforce Cosentyx long term skin
clearance and safety[1]
The digital press release with multimedia content can be accessed here:
Basel, September 13, 2017 - Novartis announced today, first of its kind Phase
III data showing Cosentyx(®) (secukinumab) delivered high and long-lasting skin
clearance in patients with moderate-to-severe plaque psoriasis at 5 years[1].
These data were presented for the first time at the 26th European Academy of
Dermatology and Venereology (EADV) Congress in Geneva, Switzerland.
By specifically targeting interleukin-17A (IL-17A), Cosentyx addresses the key
cytokine involved in the development of psoriasis[2]. IL-17A plays a significant
role in the pathogenesis of plaque psoriasis, psoriatic arthritis (PsA) and
ankylosing spondylitis (AS)[3]-[5]. Inhibiting IL-17A is important as up to 30%
of patients with psoriasis may have PsA[6],[7].
"These final data are meaningful for dermatologists as they show that the high
efficacy and safety of secukinumab was sustained over the 5-year treatment
period.", said Dr. Robert Bissonnette, Innovaderm Research, Montreal, Canada.
"The 5-year data reinforce Cosentyx as an important treatment option for those
people living with psoriasis who aspire for skin clearance that can last," said
Vas Narasimhan, Global Head, Drug Development and Chief Medical Officer,
Novartis. "Cosentyx is the first and only IL-17A inhibitor approved for
psoriasis, psoriatic arthritis and ankylosing spondylitis and has been
prescribed to more than 100,000 patients since launch."
Clear skin is the aim of psoriasis treatment, and a Psoriasis Area and Severity
Index (PASI) 75, 90 or 100 response is considered an important measure of
treatment success[8]-[11]. Over the extended treatment period from Year 1 (Week
52) to the end of Year 5 (Week 260), PASI 75/90/100 response rates remained
consistent[1]. PASI 75 and PASI 90 response rates were achieved by 89% and 69%
of psoriasis patients, respectively, at Year 1 ('as observed' analysis) and this
high rate was maintained to Year 5 (89% and 66%, respectively). In addition,
44% of psoriasis patients achieved completely clear skin (PASI 100) at Year 1
and this rate was maintained to Year 5 (41%). Cosentyx continued to have a
favorable and consistent safety profile, and low immunogenicity[1],[3].
To date, more than 100,000 patients worldwide have been prescribed Cosentyx in
the post-marketing setting across all indications[12]. In addition, 2017 marks
10 years since the first patient, first visit in a clinical trial with Cosentyx.
About Cosentyx and IL-17A
Cosentyx, launched in 2015, is the first and only fully-human IL-17A inhibitor
approved to treat psoriasis, PsA and AS[3]. Cosentyx is a targeted treatment
that specifically inhibits the IL-17A cytokine which plays a significant role in
the pathogenesis of plaque psoriasis, PsA and AS[3]-[5].
Cosentyx delivers long-lasting skin clearance, with proven sustainability,
safety out to 5 years and convenient once-monthly dosing in a patient-friendly
auto injector[13]. Cosentyx is also approved for the most difficult-to-treat
types of plaque psoriasis - palmoplantar psoriasis (psoriasis of the hands and
feet), scalp psoriasis, and nail psoriasis[3].
Cosentyx is approved in 79 countries for the treatment of moderate-to-severe
plaque psoriasis, which includes the European Union countries, Japan,
Switzerland, Australia, the US and Canada. In Europe, Cosentyx is approved for
the first-line systemic treatment of moderate-to-severe plaque psoriasis in
adult patients[3]. In the US, Cosentyx is approved as a treatment for moderate-
to-severe plaque psoriasis in adult patients who are candidates for systemic
therapy or phototherapy (light therapy)[14].
In addition, Cosentyx is the first IL-17A inhibitor approved in more than 70
countries for the treatment of active AS and PsA, which includes the European
Union countries and the US. Cosentyx is also approved for the treatment of PsA
and pustular psoriasis in Japan[12].
About the 5-year Cosentyx extension study (A2304E1)[1]
A2304E1 is a multicenter, double-blind and open-label, 5-year extension to the
pivotal Phase III SCULPTURE study. The primary objective of this extension study
was to assess the long-term safety and tolerability of Cosentyx in patients with
moderate-to-severe plaque psoriasis. Efficacy measures included the proportion
of patients achieving PASI 75, PASI 90 and PASI 100. This long-term extension
study demonstrated the sustained efficacy and safety of Cosentyx. In 162
psoriasis patients at Year 1, PASI 75 and PASI 90 response rates were achieved
by 89% and 69% of patients respectively. This high rate was maintained at Year
5 with 122 patients observed (89% and 66%, respectively). In SCULPTURE, PASI 75
responders at Week 12 were randomized to double-blind maintenance treatment of
Cosentyx 300 mg or 150 mg, given either at a 4-week fixed-interval regimen or in
a retreatment-as-needed regimen. Patients who completed 52 weeks of the
SCULPTURE study were eligible to continue the same dose and regimen in the
extension study (N=642).
About psoriasis
Psoriasis is a common, non-contagious, auto-immune disease that affects more
than 125 million people worldwide[15]. Plaque psoriasis is the most common form
of the disease and appears as raised, red patches covered with a silvery white
buildup of dead skin cells.
Psoriasis is not simply a cosmetic problem, but a persistent, chronic (long-
lasting), and sometimes distressing disease, which can affect even the smallest
aspects of people's lives on a daily basis. Up to 30% of patients with psoriasis
may develop PsA[6]. PsA is a condition in which the joints are also affected,
causing debilitating symptoms including pain, stiffness and for some people,
irreversible joint damage[6],[16]. Psoriasis is also associated with other
serious health conditions, such as diabetes, heart disease and depression[6].
About Novartis Immunology & Dermatology
Novartis is a global leader in Immunology & Dermatology. We are transforming the
lives of people living with immunologic diseases, focusing on specialty
dermatology, rheumatology, auto-inflammatory, transplant and specialty liver
diseases where high unmet medical needs exist. Our leading brand Cosentyx(®)
(secukinumab) is an innovative biologic approved in more than 70 markets for the
treatment of moderate-to-severe psoriasis (PsO), ankylosing spondylitis (AS) and
psoriatic arthritis (PsA). Other key brands include Xolair(®) (omalizumab)* in
chronic spontaneous urticaria (CSU), Zortress(®)/Certican(®) and Myfortic(®) in
transplant and Ilaris(®) (canakinumab), approved to treat several rare diseases
including some Periodic Fever Syndromes. Our I&D pipeline includes multiple
compounds in liver disease.
* Novartis co-promotes Xolair with Genentech in the US and shares a portion of
the operating income, but does not book US sales.
Disclaimer
This press release contains forward-looking statements within the meaning of the
United States Private Securities Litigation Reform Act of 1995. Forward-looking
statements can generally be identified by words such as "potential," "can,"
"will," "plan," "expect," "anticipate," "look forward," "believe," "committed,"
"investigational," "pipeline," "launch," or similar terms, or by express or
implied discussions regarding potential marketing approvals, new indications or
labeling for Cosentyx and the other investigational and approved products
described in this press release, or regarding potential future revenues from
such products. You should not place undue reliance on these statements. Such
forward-looking statements are based on our current beliefs and expectations
regarding future events, and are subject to significant known and unknown risks
and uncertainties. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those set forth in the forward-looking statements.
There can be no guarantee that Cosentyx or the other investigational or approved
products described in this press release will be submitted or approved for sale
or for any additional indications or labeling in any market, or at any
particular time. Nor can there be any guarantee that such products will be
commercially successful in the future. In particular, our expectations regarding
such products could be affected by, among other things, the uncertainties
inherent in research and development, including clinical trial results and
additional analysis of existing clinical data; regulatory actions or delays or
government regulation generally; our ability to obtain or maintain proprietary
intellectual property protection; the particular prescribing preferences of
physicians and patients; global trends toward health care cost containment,
including government, payor and general public pricing and reimbursement
pressures; general economic and industry conditions, including the effects of
the persistently weak economic and financial environment in many countries;
safety, quality or manufacturing issues, and other risks and factors referred to
in Novartis AG's current Form 20-F on file with the US Securities and Exchange
Commission. Novartis is providing the information in this press release as of
this date and does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has
leading positions globally in each of these areas. In 2016, the Group achieved
net sales of USD 48.5 billion, while R&D throughout the Group amounted to
approximately USD 9.0 billion. Novartis Group companies employ approximately
119,000 full-time-equivalent associates. Novartis products are sold in
approximately 155 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations(at)novartis.com
References
[1] Bissonnette R et al. Secukinumab demonstrates high sustained efficacy and a
favorable safety profile through 5 years of treatment in moderate to severe
psoriasis. Presented as eposter P2223 at 26th EADV Congress 2017. 13th September
2017..
[2] Zeichner JA and Armstrong A. The role of IL-17 in the pathogenesis and
treatment of psoriasis. The Journal of Clinical and Aesthetic Dermatology.
2016;9:S3-S6.
[3] Cosentyx Summary of Product Characteristics. Novartis Europharm Limited.
Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/
medicines/human/medicines/003729/human_med_001832.jsp&mid=WC0b01ac058001d124.
Last accessed September 2017.
[4] Nestle FO et al. Mechanisms of disease psoriasis. New England Journal of
Medicine. 2009;361:496-509
[5] Girolomoni G et al. Psoriasis: rationale for targeting interleukin-17.
British Journal of Dermatology. 2012;167:717-24.
[6] National Psoriasis Foundation. Psoriatic disease: about psoriasis. Available
at: www.psoriasis.org/about-psoriasis. Last accessed September 2017.
[7] Mease PJ et al.. Prevalence of rheumatologist-diagnosed psoriatic arthritis
in patients with psoriasis in European/North American dermatology clinics.
Journal of the American Academy of Dermatology. 2013;69:729-35.
[8] European Medicines Agency. Guideline on clinical investigation of medicinal
products indicated for the treatment of psoriasis. Available at:
http://www.ema.europa.eu/docs/en_GB/document_library/
Scientific_guideline/2009/09/WC500003329.pdf. Last accessed September 2017.
[9] ACTAS Dermo-Sifiliográficas. Spanish Evidence-Based Guidelines on the
Treatment of Psoriasis With Biologic Agents. Available at:
http://www.actasdermo.org/en/spanish-evidence-based-guidelines-on-
treatment/articulo/S1578219013001789/. Last accessed September 2017.
[10] Canadian Dermatology Association. Canadian Guidelines for the Management of
Plaque Psoriasis. Available at: http://www.dermatology.ca/wp-
content/uploads/2012/01/cdnpsoriasisguidelines.pdf. Last accessed September
2017.
[11] Langley RG et al. The 5-point Investigator's Global Assessment (IGA) Scale:
a modified tool for evaluating plaque psoriasis severity in clinical
trials. Journal of Dermatology Treatment. 2015;26:23-31.
[12] Novartis. Data on file. September 2017.
[13] Lacour JP et al. Secukinumab administration by autoinjector maintains
reduction of plaque psoriasis severity over 52 weeks: results of the randomized
controlled JUNCTURE trial. Journal of the European Academy of Dermatology and
Venereology. 2017;31:847-56.
[14] Cosentyx (secukinumab) [prescribing information]. East Hanover, NJ:
Novartis Pharmaceuticals Corp, 2016.
[15] International Federation of Psoriasis Associations (IFPA) World Psoriasis
Day website. "About Psoriasis." Available at:
http://www.worldpsoriasisday.com/web/page.aspx?refid=114. Last accessed
September 2017.
[16] Mease PJ and Armstrong AW. Managing patients with psoriatic disease: the
diagnosis and pharmacologic treatment of psoriatic arthritis in patients with
psoriasis. Drugs. 2014; 74:423-41.
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations(at)novartis.com
Eric Althoff Friedrich von Heyl
Novartis Global Media Relations Novartis Global Pharma Communications
+41 61 324 7999 (direct) +41 61 324 8984 (direct)
+41 79 593 4202 (mobile) +41 79 749 0286 (mobile)
eric.althoff(at)novartis.com friedrich.vonheyl(at)novartis.com
Novartis Investor Relations
Central investor relations line:
+41 61 324 7944
E-mail: investor.relations(at)novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media release (PDF):
http://hugin.info/134323/R/2133578/816046.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 13.09.2017 - 07:15 Uhr
Sprache: Deutsch
News-ID 559689
Anzahl Zeichen: 17330
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 305 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
